BIOMAT Database Logo BIOMAT Database Logo

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. 2019

Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Department of Dermatology, Amsterdam University Medical Centers, Location Vrije Universiteit Medical Center, 1081HV Amsterdam, The Netherlands. d.tio@vumc.nl.

Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM). Surgery is the gold standard but an alternative treatment is off-label topical imiquimod. The aim of this study was to evaluate the effectiveness of 5% topical imiquimod treatment for lentigo maligna. In the period 2007-2017 57 patients with lentigo maligna were treated with off-label topical imiquimod once daily for 12 weeks. Complete clinical clearance was observed in 48 patients (84.2%) and partial clearance in 3 patients (5.3%). Three patients (5.3%) showed no response and another 3 patients (5.3%) stopped treatment due to side-effects. After 4.5 years during follow-up one patient developed a lentigo maligna melanoma which was subsequently excised. Treatment with topical imiquimod resulted in complete clearance of lentigo maligna in 48 out of 57 patients (84.2%). Topical imiquimod is an acceptable treatment option for patients with lentigo maligna who prefer topical treatment to surgery or radiotherapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077271 Imiquimod A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine,Aldara,R 837,R-837,S 26308,S-26308,Zyclara,R837
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Topical Imiquimod Treatment of Lentigo Maligna.
October 2009, Case reports in dermatology,
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Topical 5% imiquimod in the treatment of lentigo maligna.
January 2012, Journal of cutaneous medicine and surgery,
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Topical treatment of lentigo maligna melanoma with imiquimod 5% cream.
January 2003, Dermatology (Basel, Switzerland),
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Treatment of lentigo maligna with topical imiquimod.
November 2003, The British journal of dermatology,
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Topical imiquimod for periocular lentigo maligna.
December 2010, Ophthalmology,
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Topical imiquimod therapy for lentigo maligna.
October 2008, Annals of plastic surgery,
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.
February 2023, Eye (London, England),
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Treatment of lentigo maligna with imiquimod 5% cream.
October 2007, Journal of drugs in dermatology : JDD,
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Extensive lentigo maligna clearing with topical imiquimod.
July 2003, Archives of dermatology,
Darryl C K S Tio, and Catherine van Montfrans, and Claire G H Ruijter, and Rick Hoekzema, and Marcel W Bekkenk
Amelanotic lentigo maligna managed with topical imiquimod.
May 2012, The Journal of dermatology,
Copied contents to your clipboard!